Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs

@article{Noble2007ProtectionOE,
  title={Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs},
  author={Florence Noble and B. Roques},
  journal={Expert Opinion on Therapeutic Targets},
  year={2007},
  volume={11},
  pages={145 - 159}
}
  • F. Noble, B. Roques
  • Published 17 January 2007
  • Medicine
  • Expert Opinion on Therapeutic Targets
The most efficient drugs to alleviate severe pain are opioid compounds. However, their chronic use could be associated with serious drawbacks, such as tolerance, respiratory depression and constipation. Therefore, there is a need for compounds able to efficiently alleviate inflammatory and neurogenic pain following chronic treatment. The discovery that the endogenous opioid peptides, enkephalins, are inactivated by two metallopeptidases, neutral endopeptidase and aminopeptidase N, which can be… 
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
TLDR
The effects of Dual enkephalinase inhibitors and FAAH inhibitors are compared and the progress in their rational design is described, to consider the challenges in their clinical development and opportunities for combination therapies.
Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management
TLDR
The physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future.
The opioidergic system: potential roles and therapeutic indications in the eye.
  • S. Husain, D. Potter
  • Medicine
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2008
TLDR
An overview of the complexity of opioid receptor-mediated pharmacologic actions in the eye is provided and evidence suggests that opioidergic ligands have the potential to protect against retinopathies, particularly those associated with glaucoma.
Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain
TLDR
In all tested models, the most efficient prodrug 2a (PL265) was active, at least during 150–180 min, after single oral administration of 2a, the active drug is the only generated metabolite produced, and these encouraging results have made 2a a suitable candidate for clinical development.
Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects.
TLDR
It is concluded that opiorphin, by inhibiting the destruction of endogenous enkephalins, activates restricted opioid pathways specifically involved in pain control, thus contributing to a greater balance between analgesia and side-effects than found with morphine.
Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways.
TLDR
It is concluded that opiorphin is able to elicit antidepressant-like effects, mediated via delta-opioid receptor-dependent pathways, by modulating the concentrations of endogenous enkephalin released in response to specific physical and/or psychological stimuli.
Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.
  • B. Roques
  • Medicine
    Handbook of experimental pharmacology
  • 2018
TLDR
These responses could be explored eitheir by using higlhy selective delta agonist or by emphasizing the effects of phasically secreted endogenous opioid peptides, enkephalin, both approaches were investigated in particular through protection of enkphalin degradation by dual enkephalase ihibitors DENKIs such as RB101, PL37 or PL265.
ynergistic combinations of the dual enkephalinase inhibitor PL 265 iven orally with various analgesic compounds acting on different argets , in a murine model of cancer-induced bone pain
Background: The first line pharmacological treatment of cancer pain is morphine and surrogates but a significant pain relief and a reduction of the side-effects of these compounds makes it necessary
Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain
TLDR
The results demonstrate the ability of PL265, a DENKI that prevents the degradation of endogenous ENKs, to counteract cancer-induced bone thermal hyperalgesia in mice, by exclusively stimulating peripheral opioid receptors as demonstrated by used of an opioid antagonist unable to enter the brain.
A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine
TLDR
It is shown that the rapidly metabolized Leu-enkephalin (LENK) neuropeptide may become pharmacologically efficient owing to a simple conjugation with the lipid squalene (SQ) in a novel nanomedicine approach, allowing the specific delivery of LENK neuropePTide into inflamed tissues for pain control.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 153 REFERENCES
Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration
TLDR
Exogenous opioids released during conditions of normal ventilation do not exert any depressant neuromodulatory effect on this function, even when their extracellular concentrations are increased by peptidase inhibitors.
Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics.
TLDR
The best inhibitors were 10x more potent than described dual inhibitors in alleviating acute and inflammatory nociceptive stimuli in mice, thus providing a basis for the development of a family of analgesics devoid of opioid side effects.
Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone
TLDR
Strong facilitatory effects of subanalgesic doses of the CCK2 receptor antagonist, PD‐134,308 or the synthetic opioid agonist, methadone on RB3007‐induced antinociceptive responses were observed, which may constitute promising data for future development of a new class of analgesics that could be of major interest in a number of severe and persistent pain syndromes.
Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management
TLDR
The synergism in antinociceptive effects observed with the combination of RB101 and morphine supported by isobolographic analysis, may have interesting clinical implications, considering both the lack of opiate drawbacks observed with RB 101 and the high potentiation of its ant inociception effects with very low doses of morphine.
Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways
TLDR
The discovery of Opiorphin is extremely exciting from a physiological point of view in the context of endogenous opioidergic pathways, notably in modulating mood-related states and pain sensation, because of its in vivo properties, and may have therapeutic implications.
Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.
TLDR
It is concluded that although the finding that some opioids are weak noncompetitive NMDA receptor antagonists in vitro has created much attention among clinicians, no clinical studies have been conducted to evaluate the applicability of these compounds in the treatment of neuropathic pain conditions.
"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes.
TLDR
The analgesic potencies of the "mixed inhibitor-prodrug" RB 101 were three times greater than those of a similar combined dose of its two constitutive moieties, and the separation of the two diastereoisomers constituting RB 101 showed that the analgesia has a stereochemical dependence.
Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes.
TLDR
The analgesic effect of [Met5]enkephalin was potentiated 50000 times by intracerebroventricular co-administration in mice of kelatorphan (50 micrograms), and Kelatorphan alone was at least two-fold more potent as analgesic than the above mixture of inhibitors.
Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
TLDR
The brain peptide cholecystokinin (CCK) has been shown to counteract the analgesic effects of morphine suggesting a physiological antagonism between opioid and CCK neural systems, and co-administration of the CCK-B selective antagonist L-365,260 with RB 101 protects the endogenous opioids, the enkephalins, from their inactivation.
Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation
TLDR
The results indicate that the endogenous opioid peptides, probably enkephalins, are important in the peripheral control of nociception from inflamed tissues.
...
1
2
3
4
5
...